Rees Frances, Doherty Michael, Grainge Matthew J, Lanyon Peter, Davenport Graham, Zhang Weiya
Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, Rheumatology Department, Nottingham University Hospitals NHS Trust,
Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham.
Rheumatology (Oxford). 2016 May;55(5):854-60. doi: 10.1093/rheumatology/kev424. Epub 2016 Jan 8.
To estimate the mortality associated with SLE during the period 1999-2012 by age, gender and region; and to ascertain the cause of death for people with SLE.
A retrospective cohort study using the UK Clinical Practice Research Datalink. Incident SLE cases diagnosed between 1999 and 2012 were matched by age, sex and practice to four controls. Age-, gender- and region-specific mortality rates were calculated per 1000 person-years and compared with control mortality rates using mortality rate ratios (MRRs). For individuals with linked Office of National Statistics data, cause of death was summarized by International Classification of Disease-10 chapter heading.
Of 2740 incident cases, 227 died, giving a mortality rate of 15.84/1000 person-years (95% CI 13.91, 18.04). This was 67% higher than in controls (MRR 1.67, 95% CI 1.43, 1.94, P < 0.001). Men with SLE had higher rates of mortality than females with SLE. Compared with controls, the mortality rate for males with SLE was 1.80 times that of male controls (95% CI 1.32, 2.45, P < 0.001); for females the mortality rate was 1.64 times higher (95% CI 1.37, 1.96, P < 0.001). The age-specific mortality rates increased significantly with age; however, the MRR diminished from 3.81 (95% CI 1.43, 10.14) in those aged <40 years to 0.82 (95% CI 0.36, 1.83) in those ⩾90 years. There was no significant difference in mortality between regions. Circulatory system disease and malignancy were the most frequent causes of death in both cases and controls.
There remains an increased mortality for people with SLE compared with matched controls, particularly at younger ages.
按年龄、性别和地区估算1999 - 2012年期间与系统性红斑狼疮(SLE)相关的死亡率;并确定SLE患者的死因。
使用英国临床实践研究数据链进行一项回顾性队列研究。1999年至2012年期间确诊的SLE新发病例按年龄、性别和医疗机构与四名对照进行匹配。计算每1000人年的年龄、性别和地区特异性死亡率,并使用死亡率比(MRR)与对照死亡率进行比较。对于与国家统计局数据相关联的个体,死因按国际疾病分类第10版章节标题进行汇总。
在2740例新发病例中,227例死亡,死亡率为15.84/1000人年(95%可信区间13.91, 18.04)。这比对照组高67%(MRR 1.67, 95%可信区间1.43, 1.94, P < 0.001)。SLE男性患者的死亡率高于SLE女性患者。与对照组相比,SLE男性患者的死亡率是男性对照的1.80倍(95%可信区间1.32, 2.45, P < 0.001);女性的死亡率高1.64倍(95%可信区间1.37, 1.96, P < 0.001)。年龄特异性死亡率随年龄显著增加;然而,MRR从<40岁人群中的3.81(95%可信区间1.43, 10.14)降至≥90岁人群中的0.82(95%可信区间0.36, 1.83)。各地区之间的死亡率无显著差异。循环系统疾病和恶性肿瘤是病例组和对照组中最常见的死因。
与匹配的对照组相比,SLE患者的死亡率仍然较高,尤其是在年轻年龄段。